-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On March 29, a total of 3 new shares were listed, namely Wankai New Materials, Fuji Lay and Taienkang, of which Fuji Lay was a new pharmaceutical stock.
The issue price was 48.
3 yuan per share, and the issue price-earnings ratio was 32.
67.
times
.
According to public information, Fujilai is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, APIs and raw materials for health care products.
The main products include lipoic acid series, phosphatidylcholine series, and carnosine series
.
Among them, lipoic acid is the core product of the company.
It belongs to the vitamin B group compound, which has the functions of scavenging free radicals and active oxygen (antioxidation), chelating metal ions, and regenerating other antioxidants
.
Lipoic acid series products are mainly used in the treatment of various diseases such as diabetic peripheral neuropathy and nervous system complications in the field of medicine, and also play a certain role in the field of health care products
.
In 2020, the export volume of the company's lipoic acid series products accounted for nearly 40%
.
This series of products has also become a major driving force for the company's revenue growth
.
The prospectus shows that from 2018 to January to June 2021, Fujilai achieved operating income of 375 million yuan, 452 million yuan, 477 million yuan and 522 million yuan respectively.
During the same period, the net profit attributable to owners of the parent company was 0.
93 yuan.
100 million yuan, 146 million yuan, 141 million yuan and 120 million yuan
.
The company attaches great importance to R&D investment.
For example, in terms of R&D innovation, the company has established a complete R&D system and a professional R&D team.
The R&D scope covers the research and development of new product routes, small-scale process optimization, experimental scale-up, pilot-scale verification production, and product quality research.
In terms of detection and impurity research and analysis; in terms of technological innovation, the company has formed a complete engineering equipment system, mature and stable manufacturing processes, strong industrialization capabilities, standardized quality control systems, and established a complete and diversified chemical reaction system, and the products have independent intellectual property rights, with strong cost advantages and quality competitiveness
.
At the same time, the company has carried out further process optimization and application expansion research on some core products to improve product quality and production efficiency, expand the potential market of products, and build a corporate moat with core technologies
.
On the basis of the existing lipoic acid series, carnosine series and phosphatidylcholine series products, Fujiray also focuses on the development of characteristic APIs, including erecoxib APIs, apatinib APIs and lipoic acid raw materials medicine project
.
In the future, the company's product structure will be further enriched with the successive approvals for production and sales of the company's under-development API projects
.
In recent years, in the context of the rapid development of the pharmaceutical industry, the size of the API market has continued to grow
.
According to the Mordor Intelligence report, the global API market size in 2020 is approximately US$174.
96 billion, and is expected to reach US$245.
88 billion by 2026, with a forecast compound annual growth rate of 5.
84% from 2021 to 2026
.
As the focus of the world's API production begins to shift to developing countries, China's API and intermediate industry has a promising prospect.
The industry expects that leading API and intermediate companies with distinctive competitiveness are expected to embrace the opportunity
.
It is reported that Fujifilm was listed on the New Third Board in October 2015 and delisted in March 2019.
The company had a successful IPO in 2017 but was unsuccessful, and now it is finally listed on the GEM of the Shenzhen Stock Exchange
.
The company plans to raise 670 million yuan this time, which will be used for 720 tons of pharmaceutical intermediates and API projects, so as to break through the bottleneck of production capacity, continuously expand the market share of existing products, and consolidate the market position of existing core products
.
The company also plans to cooperate with pharmaceutical preparation companies to develop CMO/CDMO business, build a series of sustainable product echelons, promote the company's business upgrade, strengthen the company's core competitiveness, and enhance sustainable profitability
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The issue price was 48.
3 yuan per share, and the issue price-earnings ratio was 32.
67.
times
.
According to public information, Fujilai is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, APIs and raw materials for health care products.
The main products include lipoic acid series, phosphatidylcholine series, and carnosine series
.
Among them, lipoic acid is the core product of the company.
It belongs to the vitamin B group compound, which has the functions of scavenging free radicals and active oxygen (antioxidation), chelating metal ions, and regenerating other antioxidants
.
Lipoic acid series products are mainly used in the treatment of various diseases such as diabetic peripheral neuropathy and nervous system complications in the field of medicine, and also play a certain role in the field of health care products
.
In 2020, the export volume of the company's lipoic acid series products accounted for nearly 40%
.
This series of products has also become a major driving force for the company's revenue growth
.
The prospectus shows that from 2018 to January to June 2021, Fujilai achieved operating income of 375 million yuan, 452 million yuan, 477 million yuan and 522 million yuan respectively.
During the same period, the net profit attributable to owners of the parent company was 0.
93 yuan.
100 million yuan, 146 million yuan, 141 million yuan and 120 million yuan
.
The company attaches great importance to R&D investment.
For example, in terms of R&D innovation, the company has established a complete R&D system and a professional R&D team.
The R&D scope covers the research and development of new product routes, small-scale process optimization, experimental scale-up, pilot-scale verification production, and product quality research.
In terms of detection and impurity research and analysis; in terms of technological innovation, the company has formed a complete engineering equipment system, mature and stable manufacturing processes, strong industrialization capabilities, standardized quality control systems, and established a complete and diversified chemical reaction system, and the products have independent intellectual property rights, with strong cost advantages and quality competitiveness
.
At the same time, the company has carried out further process optimization and application expansion research on some core products to improve product quality and production efficiency, expand the potential market of products, and build a corporate moat with core technologies
.
On the basis of the existing lipoic acid series, carnosine series and phosphatidylcholine series products, Fujiray also focuses on the development of characteristic APIs, including erecoxib APIs, apatinib APIs and lipoic acid raw materials medicine project
.
In the future, the company's product structure will be further enriched with the successive approvals for production and sales of the company's under-development API projects
.
In recent years, in the context of the rapid development of the pharmaceutical industry, the size of the API market has continued to grow
.
According to the Mordor Intelligence report, the global API market size in 2020 is approximately US$174.
96 billion, and is expected to reach US$245.
88 billion by 2026, with a forecast compound annual growth rate of 5.
84% from 2021 to 2026
.
As the focus of the world's API production begins to shift to developing countries, China's API and intermediate industry has a promising prospect.
The industry expects that leading API and intermediate companies with distinctive competitiveness are expected to embrace the opportunity
.
It is reported that Fujifilm was listed on the New Third Board in October 2015 and delisted in March 2019.
The company had a successful IPO in 2017 but was unsuccessful, and now it is finally listed on the GEM of the Shenzhen Stock Exchange
.
The company plans to raise 670 million yuan this time, which will be used for 720 tons of pharmaceutical intermediates and API projects, so as to break through the bottleneck of production capacity, continuously expand the market share of existing products, and consolidate the market position of existing core products
.
The company also plans to cooperate with pharmaceutical preparation companies to develop CMO/CDMO business, build a series of sustainable product echelons, promote the company's business upgrade, strengthen the company's core competitiveness, and enhance sustainable profitability
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
